Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 63

recruiting
3 972
countries
28
conditions
2 103

1 070 trials match your criteria

Study on the Effects of Sparsentan and Irbesartan for Patients with Primary Focal Segmental Glomerulosclerosis (FSGS)

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Irbesartan

Long-term Study of Sotatercept for Adults with Pulmonary Arterial Hypertension (PAH)

InvestigationalNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Sotatercept

Plasma cell myeloma

Not recruiting

Study on Isatuximab and CellProtect for Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplant

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Evencaleucel

Liver operation

Not recruiting

Study on Lidocaine and Sodium Chloride for Patients Undergoing Liver Tumor Surgery

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Lidocaine

Study of GEN3014 and Daratumumab for Patients with Relapsed or Refractory Multiple Myeloma and Other Blood Cancers

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab

EGFR gene mutation+1

Not recruiting

Study on the Effectiveness and Safety of BAY 2927088 Compared to Standard Treatment in Patients with Advanced Non-Small Cell Lung Cancer with HER2 Mutations

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:BAY 2927088

Study Comparing Bomedemstat and Hydroxycarbamide for Patients with Essential Thrombocythemia

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Bomedemstat

Study on the Safety and Effects of RLYB212 in Pregnant Women at Risk for Fetal and Neonatal Alloimmune Thrombocytopenia

InvestigationalNo placebo
Countries:SwedenSweden
  • Participants:18–64 years
  • Substances:Anti-(integrin BETA-3) human monoclonal antibody

Ovarian cancer

Not recruiting

Study on the Safety and Tolerability of KAND567 and Carboplatin for Women with Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Study on the Effect of Extending Imatinib Treatment from Three to Five Years for Patients with High-Risk Gastrointestinal Stromal Tumor (GIST)

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib

Major depression

Not recruiting

Study on the Safety and Effectiveness of Aticaprant with Antidepressants for Adults and Elderly with Major Depressive Disorder

InvestigationalNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Aticaprant

Malignant glioma

Not recruiting

Study of tovorafenib versus standard chemotherapy as first treatment for children with low-grade glioma with RAF gene changes

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:0–17 years · 18–64 years
  • Substances:Carboplatin
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.